Agile Therapeutics, Inc. (NASDAQ:AGRX) – Stock analysts at Cantor Fitzgerald issued their FY2016 earnings estimates for Agile Therapeutics in a research report issued on Tuesday. Cantor Fitzgerald analyst C. Russo forecasts that the firm will post earnings of ($1.14) per share for the year. Cantor Fitzgerald has a “Buy” rating and a $7.00 price target on the stock. Cantor Fitzgerald also issued estimates for Agile Therapeutics’ FY2017 earnings at ($1.42) EPS.

A number of other brokerages have also commented on AGRX. FBR & Co reiterated a “buy” rating and issued a $16.00 price objective on shares of Agile Therapeutics in a research report on Tuesday, November 8th. RBC Capital Markets reiterated an “outperform” rating and issued a $8.00 price objective (down from $15.00) on shares of Agile Therapeutics in a research report on Thursday, January 5th. Finally, Janney Montgomery Scott reiterated a “buy” rating and issued a $15.00 price objective on shares of Agile Therapeutics in a research report on Thursday, January 5th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Agile Therapeutics presently has an average rating of “Buy” and a consensus target price of $11.00.

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Daily Political and is the propert of of Daily Political. If you are viewing this piece of content on another website, it was illegally stolen and republished in violation of international trademark and copyright legislation. The legal version of this piece of content can be viewed at http://www.dailypolitical.com/2017/01/13/cantor-fitzgerald-weighs-in-on-agile-therapeutics-inc-s-fy2016-earnings-agrx.html.

Shares of Agile Therapeutics (NASDAQ:AGRX) remained flat at $2.56 during trading on Friday. 461,786 shares of the stock traded hands. The company’s 50-day moving average is $6.26 and its 200 day moving average is $6.97. The company’s market capitalization is $73.62 million. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $8.65.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, November 7th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.08.

Several institutional investors have recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC boosted its position in Agile Therapeutics by 1.2% in the third quarter. Rice Hall James & Associates LLC now owns 25,631 shares of the specialty pharmaceutical company’s stock valued at $179,000 after buying an additional 314 shares during the period. Hamilton Lane Advisors LLC acquired a new position in Agile Therapeutics during the third quarter valued at $387,000. Bridgeway Capital Management Inc. boosted its position in Agile Therapeutics by 66.8% in the second quarter. Bridgeway Capital Management Inc. now owns 112,334 shares of the specialty pharmaceutical company’s stock valued at $855,000 after buying an additional 45,000 shares during the period. State Street Corp boosted its position in Agile Therapeutics by 34.2% in the second quarter. State Street Corp now owns 133,438 shares of the specialty pharmaceutical company’s stock valued at $1,015,000 after buying an additional 34,033 shares during the period. Finally, Perceptive Advisors LLC boosted its stake in Agile Therapeutics by 193.9% in the second quarter. Perceptive Advisors LLC now owns 514,288 shares of the specialty pharmaceutical company’s stock valued at $3,914,000 after buying an additional 339,288 shares during the last quarter. Institutional investors and hedge funds own 83.50% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Daily Political and is the propert of of Daily Political. If you are viewing this piece of content on another website, it was illegally stolen and republished in violation of international trademark and copyright legislation. The legal version of this piece of content can be viewed at http://www.dailypolitical.com/2017/01/13/cantor-fitzgerald-weighs-in-on-agile-therapeutics-inc-s-fy2016-earnings-agrx.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

5 Day Chart for NASDAQ:AGRX

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.